Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology | GenomeWeb

Traversa Therapeutics this month closed a Series B round worth $5 million, RNAi News has learned.

The cash infusion, combined with an expected revenue stream related to the sale of research products incorporating the company's RNAi-delivery technology, is expected to give the firm enough cash to fund its planned operations through 2010, Traversa President and CEO Hans Petersen told RNAi News yesterday.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.